UK drugmaker GSK is struggling to convince the market that it can deliver on its plans to refill its pipeline ahead of a key patent expiry, as US hedge fund Citadel took the largest short position ...

GSK Plc is a long-term underperformer among Europe’s Big Pharma stocks. And with key drug patents set to expire and vaccine ...

NEW YORK CITY, NY / ACCESS Newswire / February 21, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law ...

Shares of GSK PLC GSK rose 1.79% to £14.47 Thursday, on what proved to be an all-around rough trading session for the stock ...

The PMCPA has turned party pooper, coming down on GSK after learning that a U.K. employee celebrated a post about a ...

The Government of Canada has secured an initial supply of 500,000 doses of GSK's bird flu vaccine to protect individuals most ...

Canada has announced a deal to secure 500K doses of GSK’s (NYSE:GSK) avian influenza vaccine for humans as the country steps ...

Allworth Financial LP boosted its stake in shares of GSK plc (NYSE:GSK – Free Report) by 175.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange ...

International biotechnology company GlaxoSmithKline is moving its vaccine and infectious disease research teams to Cambridge, ...

GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...

Billionaire Ken Griffin's hedge fund Citadel has taken a short position in British drugmaker GSK , the Financial Times ...

GSK PLC closed 20.87% below its 52-week high of £18.24, which the company reached on May 16th.